Andy Chen
Stock Analyst at Wolfe Research
(4.38)
# 386
Out of 5,033 analysts
41
Total ratings
53.85%
Success rate
25.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Downgrades: Peer Perform | n/a | $53.91 | - | 2 | Oct 10, 2025 | |
| ETNB 89bio | Downgrades: Peer Perform | n/a | $14.80 | - | 2 | Sep 19, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Peer Perform | n/a | $491.22 | - | 3 | Aug 4, 2025 | |
| VERA Vera Therapeutics | Downgrades: Peer Perform | n/a | $30.20 | - | 2 | Aug 4, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $49 | $56.26 | -12.90% | 1 | Jun 17, 2025 | |
| SRPT Sarepta Therapeutics | Initiates: Peer Perform | n/a | $23.05 | - | 1 | Jun 17, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $55 | $49.01 | +12.22% | 1 | Jun 17, 2025 | |
| MLTX MoonLake Immunotherapeutics | Upgrades: Outperform | $61 | $9.36 | +552.06% | 3 | May 19, 2025 | |
| NTLA Intellia Therapeutics | Upgrades: Outperform | $21 | $27.98 | -24.95% | 2 | Apr 21, 2025 | |
| ANAB AnaptysBio | Initiates: Outperform | n/a | $35.27 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $42.45 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $27.48 | -27.22% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $26.21 | -27.51% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $19.22 | - | 2 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $697 | $849.46 | -17.95% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $86.17 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $27.67 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $65 | $60.50 | +7.44% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $439.97 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $24.09 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $33.67 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $73.55 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $73.97 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $17.74 | -4.17% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $419.10 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $167.91 | -74.99% | 1 | Feb 15, 2024 |
Akero Therapeutics
Oct 10, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $53.91
Upside: -
89bio
Sep 19, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $14.80
Upside: -
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Peer Perform
Price Target: n/a
Current: $491.22
Upside: -
Vera Therapeutics
Aug 4, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $30.20
Upside: -
BridgeBio Pharma
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $56.26
Upside: -12.90%
Sarepta Therapeutics
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $23.05
Upside: -
Avidity Biosciences
Jun 17, 2025
Initiates: Outperform
Price Target: $55
Current: $49.01
Upside: +12.22%
MoonLake Immunotherapeutics
May 19, 2025
Upgrades: Outperform
Price Target: $61
Current: $9.36
Upside: +552.06%
Intellia Therapeutics
Apr 21, 2025
Upgrades: Outperform
Price Target: $21
Current: $27.98
Upside: -24.95%
AnaptysBio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $35.27
Upside: -
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $42.45
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $27.48
Upside: -27.22%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $26.21
Upside: -27.51%
Jan 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $19.22
Upside: -
Nov 12, 2024
Upgrades: Outperform
Price Target: $697
Current: $849.46
Upside: -17.95%
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $86.17
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $27.67
Upside: -
Aug 26, 2024
Upgrades: Outperform
Price Target: $65
Current: $60.50
Upside: +7.44%
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $439.97
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $24.09
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $33.67
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $73.55
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $73.97
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $17.74
Upside: -4.17%
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $419.10
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $167.91
Upside: -74.99%